MedTrace Logo

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

NCT00169169 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2005-09-15

No results posted yet for this study

Summary

Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.

Conditions

  • CD20-Positive Large B-Cell Lymphoma

Interventions

DRUG

ACVBP

DRUG

ACE

DRUG

rituximab

PROCEDURE

Autologous stem cell transplant

Sponsors & Collaborators

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Corinne Haioun · Hôpital Henri Mondor, Créteil, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Completion
2005-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169169 on ClinicalTrials.gov